MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Preveceutical Med Inc New (OP:PRVCF)

0.0161 UNCHANGED
Streaming Delayed Price Updated: 10:16 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0161
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0161
Today's Range 0.0161 - 0.0161
52wk Range 0.0037 - 0.0436
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is... 
Via Newsfile
Topics Intellectual Property
News headline image
BioGene Therapeutics Inc. Appoints Dr. Francis Tavares, PhD., as Chief Technology Officer
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the... 
Via Newsfile

Performance

YTD
-10.1%
-10.1%
1 Month
-0.6%
-0.6%
3 Month
-15.7%
-15.7%
6 Month
-34.6%
-34.6%
1 Year
-21.5%
-21.5%

More News

Read More
News headline image
BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research
Via Newsfile
Topics Intellectual Property
News headline image
PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting
Via Newsfile
News headline image
PreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology Officer
Via Newsfile
News headline image
PreveCeutical Welcomes Dr. Deepak Sampath, PhD. as Corporate Advisor
Via Newsfile
Topics Intellectual Property
News headline image
PreveCeutical Welcomes Stephen Glover as Corporate Advisor
Via Newsfile
News headline image
PreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative Therapies
Via Newsfile
News headline image
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
Via Newsfile
Topics Intellectual Property
News headline image
PreveCeutical Medical - Sol-Gel and Uses thereof Patent Update
Via Newsfile
Topics Intellectual Property
News headline image
PreveCeutical Medical Launches Clinical Artificial Intelligence Division
Via Newsfile
Topics Artificial Intelligence
News headline image
PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain
Via Newsfile
News headline image
PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
Via Newsfile
News headline image
PreveCeutical - International Filing of Thermoresponsive Sol-Gels Containing Cannabinoids & Uses Thereof
Via Newsfile
Topics Intellectual Property
News headline image
Appointment of C. Evan Ballantyne to PreveCeutical's Board of Directors
Via Newsfile
News headline image
PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development
Via Newsfile
News headline image
PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds
Via Newsfile
Topics Bonds Intellectual Property
News headline image
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Via Newsfile
Topics Bonds Intellectual Property
News headline image
PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update
Via Newsfile
Topics Intellectual Property
News headline image
PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals
Via Newsfile
News headline image
PreveCeutical Signs Intercompany Sol-Gel License Agreement
Via Newsfile
Topics Intellectual Property
News headline image
Appointment of Sachin Nanavati to PreveCeutical's Board of Directors
Via Newsfile
News headline image
PreveCeutical Files International Patent Application for Sol-Gel Cannabinoid Formulation for Antiviral Use
Via Newsfile
Topics Cannabis Death Intellectual Property
News headline image
PreveCeutical Signs License Agreement for Exclusive Rights to Use UniQuest's Sol-Gel Technology for Delivery of Cannabinoids
Via Newsfile
Topics Intellectual Property
News headline image
PreveCeutical Files International Patent Application for its Dynorphin Peptides
Via Newsfile
Topics Cannabis Intellectual Property

Frequently Asked Questions

Is Preveceutical Med Inc New publicly traded?
Yes, Preveceutical Med Inc New is publicly traded.
What exchange does Preveceutical Med Inc New trade on?
Preveceutical Med Inc New trades on the OTC Traded
What is the ticker symbol for Preveceutical Med Inc New?
The ticker symbol for Preveceutical Med Inc New is PRVCF on the OTC Traded
What is the current price of Preveceutical Med Inc New?
The current price of Preveceutical Med Inc New is 0.0161
When was Preveceutical Med Inc New last traded?
The last trade of Preveceutical Med Inc New was at 02/12/26 10:16 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story